Abstract 5822
Background
The real life experience in clinical arena can be challenging for student nurses, to cope with the patients’ suffering, to provide care, to communicate with them and their caregivers as death approaches .It is essential to understand student nurses’ feelings when confronted a dying patient, so that specific training, consultation and empowerment give them prior to their clinical placement. However, there has been little research in Greece on student nurses’ experience when facing care of patients and their caregivers in the last days of life.The purpose of this study was to explore undergraduate student nurse’s experience facing death and dying of a patient during their clinical practice.
Methods
A qualitative, descriptive design was used. Qualitative data were collected in June 2018 from 4th -year nursing students’ of Nursing School of National and Kapodistrian University of Athens. Experiences were collected through written reflections to obtain data about their experience when cared for a serious ill patient and when delivered their care to a dying patient and their caregivers. A content analysis of their comments was carried out.
Results
From 101 undergraduated nurses 42 answered in open-ended question “Please describe the death experience of a patient during your clinical practice”. The response rate was 41,6%.The average age of the students was 22.Nursing students’ comments revealed concerns on handling the family/caregivers of the dying patient, their willingness to care for body of the dying, expressing their emotions such as sadness, describing death experience using medical terminology and using their previous personal experiences and knowledge to handle with . Thus five categories were emerged, the concept of “family/caregivers issues” “participation in the care of the dying” “description of the event using medical terminology”, “expressing emotions positive or negative” and “referring to their previous experience and knowledge” respectively.
Conclusions
Study’s findings highlighted the influence of knowledge, personal attitudes and clinical stressors that student nurses faced in a clinical practice when they were training in palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract